# A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

> **NCT02116569** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT02116569
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2016-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02116569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02116569, "A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02116569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*